Abstract. Doxorubicin is an anti-neoplastic agent with cardiotoxicity as a side effect. We previously demonstrated that doxorubicin treatment of mice resulted in a selective decrease in expression of the Nd1 gene, which encoded a new kelch family actin binding protein in the heart. Here we show that doxorubicin treatment also reduced the Nd1 expression in various organs of mice and cultured cell lines. The treatment of Nd1-transgenic mice and Nd1-transfectants also selectively reduced levels of the exogenous Nd1 mRNAs, whose expression was under the control of various promoters. Furthermore, the doxorubicin-induced reduction of Nd1 mRNA expression in NIH3T3 cells was inhibited by treatment of these cells with cycloheximide. Thus, the doxorubicin treatment may specifically reduce the stability of Nd1 mRNA.
Introduction
Doxorubicin is an anthracycline antibiotic widely used for cancer chemotherapy. Its use is limited by the frequent incidence of dose-dependent chronic cardiomyopathy. Several mechanisms of the doxorubicin-induced cardiomyopathy are reported, including direct DNA damage and interference with DNA repair (1) , the formation of free reactive oxygen radicals (2) , and cytoskeletal changes (3) . Cytoskeletal changes following doxorubicin treatment include reduction in the density of myofibrillar bundles, alterations on the Z-disc structure, and disarray and depolimerization of actin filaments (4) . Several studies have suggested the interaction of doxorubicin with myofibrillar proteins in the etiology of doxorubicin cardiotoxicity (3, 4) . However, the molecular basis of doxorubicin-induced cardiotoxicity is not yet known.
We have recently identified a novel actin binding protein, Nd1, which belongs to a kelch family (5) . The Nd1 gene expresses two forms of splicing variants of the primary transcript. The long form of Nd1 (Nd1-L) contains a BTB/POZ domain in its N terminus and 6 kelch repeats in the C terminus. The short form (Nd1-S) has a BTB/POZ domain but lacks kelch repeats. Nd1-L mRNA is ubiquitously expressed in normal mouse tissues, most abundantly in the heart. Promoter analysis revealed that the expression of the Nd1 gene was regulated as a housekeeping gene (6) . The Nd1-L mRNA level did not change throughout the cell cycle nor after activation in lymphocytes. We used a mouse model of doxorubicin-induced cardiomyopathy to elucidate the function of Nd1 in the heart. Expression of Nd1-L in the heart decreased after administration of doxorubicin in mice. Furthermore, overexpression of Nd1-L in cardiac myocytes of transgenic mice reduced doxorubicin toxicity (Matsudo et al, unpublished data). Thus, Nd1-L plays an important role in protecting doxorubicin toxicity in cardiac myocytes (7) . However, the mechanism responsible for these phenomena is not yet understood. In this study, we address a possible mechanism of alteration of Nd1 gene expression by doxorubicin treatment. We show that the stability of Nd1 mRNA may be specifically reduced in cultured cell lines and various mouse tissues by doxorubicin treatment.
Materials and methods
Northern blot analysis. Total RNAs were extracted from adult mouse tissues and some cultured cell lines with TRIzol reagent (GIBCO-BRL, Rockville, MD). Twenty micrograms of total RNA were loaded on a 1% agarose gel in MOPS buffer containing 6% formaldehyde, transferred to a nylon membrane (Roche Diagnostic, Mannheim, Germany), and fixed by cross linking with UV irradiation. The filter was hybridized with digoxigenin (DIG) labeled probe overnight at 50˚C. Following hybridization, the filter was washed twice with 0.1X SSC and 0.1% SDS at 58˚C for 15 min. The probe on the filter was detected with sheep anti-DIG Abs conjugated with alkaline phosphatase. The antibody detection reaction was performed using an enhanced chemiluminescent detection system (Roche Diagnostic (8) . Cadmium inducible expression plasmids (pSMT-2HA-Nd1-S) were described previously (5).
Cell culture and transfection. NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum at 37˚C under 5% CO 2 . To establish stable transfectants, NIH3T3 cells were transfected with 10 μg of pSMT-2HA-Nd1-S along with 1 μg of pSV2Neo using electroporation and selected with 400 μg/ml G418 (Sigma). For induction of the SMT promoter, cells were cultured in the presence of 5 μM CdCl 2 . WEHI231 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum at 37˚C under 5% CO 2 . In some experiments, 0.1 μM of doxorubicin (Sigma) or 10 μg /ml of cycloheximide (CHX) (Sigma) were added to the culture.
Doxorubicin treatment of mice.
A simple procedure for inciting doxorubicin-induced cardiomyopathy in mice has been previously described (9) . Doxorubicin hydrochloride (Sigma) was dissolved in distilled water just before use. Mice were administered 5 mg/kg of doxorubicin intraperitoneally 4 times in 3-or 4-day intervals for 10 days. The care of all animals used in the present study was in accordance with Chiba University Animal Care guidelines.
Densitometry analysis.
In some experiments, digitized measurements were investigated quantitatively by using NIH Image software.
Results

Reduction of Nd1-L mRNA expression in various mouse organs and cultured cell lines after doxorubicin treatment.
The anthracycline antibiotic doxorubicin is an antineoplastic agent that has a cardiotoxic effect. We previously observed that the expression of Nd1-L mRNA in cardiac muscle decreased after doxorubicin treatment (Matsudo et al, unpublished data). In order to examine whether the effect of doxorubicin on Nd1 mRNA expression was restricted to cardiac muscles, we examined the expression of Nd1-L in various organs of 6-week-old mice injected with doxorubicin 4 times. Nd1-L mRNA levels in the skeletal muscle, liver, lung (Fig. 1A-C ) and spleen (data not shown) transiently increased 1 week and then decreased 3 weeks after treatment. However, the expression did not change in the kidney during the course of treatment (Fig. 1D) . Next, we examined the effect of doxorubicin in cultured cell lines. NIH3T3 cells were cultured in the presence of 0.1 μM doxorubicin, and Nd1-L mRNA expression in these cells was examined. The expression transiently increased within 1 day and then decreased 2 days after treatment (Fig. 2) . This reduction of mRNA expression was also observed in other cell lines such as WEHI231 (Fig. 3A) and 293T (data not shown). Thus, doxorubicin reduced expression of the Nd1-L gene in various organs and cell lines.
Since Nd1 encodes two types of mRNA, Nd1-L and Nd1-S (6), we examined the effect of doxorubicin on Nd1-S expression. When WEHI231 cells were cultured in the presence of doxorubicin, the expression of both Nd1-L and Nd1-S mRNA was reduced within 24 h after treatment (Fig. 3A) . Although actin mRNA decreased slightly, the reduction of Nd1 mRNAs was much more distinct, suggesting that Nd1 mRNAs are susceptible to doxorubicin treatment (Fig. 3B) .
Post-transcriptional regulation of Nd1 mRNA by doxorubicin treatment. We next examined whether the doxorubicin treatment affected transcription of the Nd1 gene or Nd1 mRNA stability. In order to examine the effect of doxorubicin on the Nd1 promoter, we utilized Nd1-L transgenic mice (Nd1-L Tg), which carried the exogenous Nd1-L gene under the control of chicken ß actin promoter (Matsudo et al, unpublished data). The sizes of these endogenous and transgenic Nd1-L mRNAs were 3.2 kb and 3.1 kb, respectively, and these were distinguishable by Northern blot analysis. Amounts of both endogenous and exogenous Nd1-L mRNAs decreased 4 weeks after doxorubicin treatment (Fig. 4) . To further examine the effect on the promoter of the Nd1 gene, we used NIH3T3 cells stably transfected with the Nd1-S gene under the control of the sheep metallothionein promoter (10) . When these transfectants were cultured in the presence of doxorubicin, the amount of exogenous Nd1-S mRNA decreased within 2 days (Fig. 5) . These data suggested that the reduction of Nd1 mRNAs after doxorubicin treatment is not due to the negative effect of doxorubicin on the Nd1 promoter activity.
Finally, we examined the effect of CHX on the stability of Nd1 mRNA. NIH3T3 cells were cultured with doxorubicin in the presence of CHX, which can stabilize any mRNAs sensitive to a short-lived RNase (11) . The amount of Nd1-L mRNA in NIH3T3 cells cultured without doxorubicin did not change in the presence of CHX, indicating that Nd1-L mRNA itself was stable (Fig. 6A) . When these cells were cultured with doxorubicin in the presence of CHX, the decrease of Nd1-L mRNA was inhibited while the amount of G3PDH was not affected (Fig. 6B) . These data suggest that Nd1-L mRNA is actively degraded in the presence of doxorubicin. Thus, doxorubicin specifically affects the Nd1 mRNA stability at post-transcriptional level in various organs and cell lines.
Discussion
In this study, we demonstrated the effect of doxorubicin on Nd1 mRNA expression. Expression of Nd1 mRNA decreased in cultured cell lines and in most mouse tissues after doxorubicin treatment. Since the decrease of Nd1 mRNA was inhibited by the treatment of cells with CHX, doxorubicin affected the stability of Nd1 mRNA, and the Nd1 mRNA destabilization was dependent on de novo protein synthesis. We originally considered the possibility that the selectivity of doxorubicin on Nd1 mRNA might in fact result from a nonspecific inhibition of gene expression and shorter half-lives for Nd1 transcripts. However, Nd1 mRNA was more sensitive to doxorubicin compared to other mRNAs from cytoskeletal and housekeeping genes.
Furthermore, the steady state of Nd1 mRNA expression in NIH3T3 cells was not affected by the addition of CHX (Fig. 6A) . Thus, there might be a specific mechanism to target the Nd1 mRNA by doxorubicin.
Doxorubicin was reported to modify the expression of several genes. Alteration of the expression of these genes was responsible for doxorubicin-induced cardiomyopathy. Doxorubicin alters transcriptional events specific to the myocardium (12) (13) (14) (15) . Doxorubicin also inhibits the transcription of muscle specific genes in skeletal muscle cells without affecting the transcription of housekeeping genes (16) . Doxorubicin induced an increased stability of porphobillinogen deaminase (PBGD) and GATA1 mRNAs in the post-transcriptionally K562 human erythroleukemic cell line (17) . The transcription rate of PBGD and GATA1 was unchanged in the doxorubicin-treated cells. Expression of the hepatitis B virus X (HBx) gene mRNA transcript was upregulated after doxorubicin treatment in HBx expressing cells and HBx transgenic mice (18) . The half-life of HBx mRNA was prolonged at post-transcriptional level in the presence of doxorubicin. The mechanisms of post-transcriptional modification by doxorubicin in these genes are not fully understood. Iron regulatory proteins (IRP) modulate the fate of mRNAs for transferrin receptor and ferritin (19) (20) (21) (22) . When the cell needs iron, IRP-1 binds to the iron responsive element in the mRNA for transferrin receptor, or increasing the stability of the mRNA. Doxorubicin irreversibly inactivates IRP in cardiomyocytes and affects the stability of transferrin receptor mRNA indirectly (23, 24) . It is possible that doxorubicin modifies expression of a protein that is responsible for stabilizing the Nd1 mRNA specifically. Since both Nd1-L and Nd1-S mRNAs are decreased by doxorubicin, mRNA encoding the BTB/POZ domain may be responsible for stabilization of the mRNA. Further study is required to identify a factor to regulate Nd1 mRNA stability induced by doxorubicin.
The anthracyclines produce a wide range of biochemical effects that have potentially toxic consequences for mammalian cells. There are several hypotheses to explain doxorubicin toxicity. One mechanism is mediated by the intercalation of the drug to DNA. This appears to be the major determinant of doxorubicin cytotoxicity to tumor cells. The other mechanism involves generation of oxygen free radicals. This appears to play a major role in the development of cardiomyopathy. We demonstrated that the cytotoxicity induced by doxorubicin is associated with alterations in the gene(s) important for the cytoskeletal structural integrity. Moreover, decrease of Nd1 gene expression was observed after incubation of cultured cell lines with 0.1 μM doxorubicin, a concentration lower than the plasma peaks observed in patients after standard doses of the doxorubicin chemotherapy (7~10 μM) (25) . It is possible that Nd1 mRNA degradation is one of the primary targets of the doxorubicin cytotoxicity. The effects of doxorubicin on Nd1 mRNA stability observed in this study facilitate the design of new anticancer chemotherapy. For example, selective inhibition of Nd1 mRNA degradation in cardiomyocytes prevents doxorubicin-induced cardiomyopathy during cancer treatment. Alternatively, selective degradation of Nd1-L mRNA in tumor cells may provide an additive effect to cancer chemotherapy.
In summary, our experiments demonstrated that doxorubicin modifies the stability of Nd1 mRNA post- transcriptionally in various tissues. Our results present significant new information regarding the effects of doxorubicin on the regulation of Nd1 mRNA, and this may be important in terms of designing novel antitumor therapies.
